JP3424978B2 - 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤 - Google Patents

単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤

Info

Publication number
JP3424978B2
JP3424978B2 JP09411494A JP9411494A JP3424978B2 JP 3424978 B2 JP3424978 B2 JP 3424978B2 JP 09411494 A JP09411494 A JP 09411494A JP 9411494 A JP9411494 A JP 9411494A JP 3424978 B2 JP3424978 B2 JP 3424978B2
Authority
JP
Japan
Prior art keywords
chemical
compound
mmol
bile acid
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP09411494A
Other languages
English (en)
Japanese (ja)
Other versions
JPH072891A (ja
Inventor
ハイナー・グロムビク
アルフオンス・エンゼン
ヴエルナー・クラーマー
ギユンター・ヴエス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of JPH072891A publication Critical patent/JPH072891A/ja
Application granted granted Critical
Publication of JP3424978B2 publication Critical patent/JP3424978B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP09411494A 1993-05-08 1994-05-06 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤 Expired - Lifetime JP3424978B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4315439:5 1993-05-08
DE4315439 1993-05-08

Publications (2)

Publication Number Publication Date
JPH072891A JPH072891A (ja) 1995-01-06
JP3424978B2 true JP3424978B2 (ja) 2003-07-07

Family

ID=6487634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09411494A Expired - Lifetime JP3424978B2 (ja) 1993-05-08 1994-05-06 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤

Country Status (18)

Country Link
US (1) US5610151A (OSRAM)
EP (1) EP0624594B1 (OSRAM)
JP (1) JP3424978B2 (OSRAM)
KR (1) KR100333151B1 (OSRAM)
AT (1) ATE183191T1 (OSRAM)
AU (1) AU673419B2 (OSRAM)
CA (1) CA2123052C (OSRAM)
CZ (1) CZ289209B6 (OSRAM)
DE (1) DE59408602D1 (OSRAM)
DK (1) DK0624594T3 (OSRAM)
ES (1) ES2136677T3 (OSRAM)
FI (1) FI942077A7 (OSRAM)
GR (1) GR3031541T3 (OSRAM)
HU (1) HUT67574A (OSRAM)
IL (1) IL109580A (OSRAM)
NO (1) NO304794B1 (OSRAM)
NZ (1) NZ260471A (OSRAM)
TW (1) TW289021B (OSRAM)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0573848T3 (da) * 1992-06-12 1998-08-10 Hoechst Ag Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
TW289020B (OSRAM) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19845403B4 (de) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19849722A1 (de) * 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
ATE241386T1 (de) * 1998-12-23 2003-06-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren
CA2356156A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
EP1340510A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
CA2356607A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
EP1354604A1 (en) * 1998-12-23 2003-10-22 G.D. Searle LLC. Combinations for cardiovascular indications
PT1140184E (pt) * 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
EA004231B1 (ru) 1998-12-23 2004-02-26 Джи.Ди.Сирл Ллс Сочетание ингибиторов белка, переносящего эфир холестерила, и производных фибриновой кислоты для сердечно-сосудистых показаний
DE19941764A1 (de) 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
PL353992A1 (en) * 1999-09-22 2003-12-15 Aventis Pharma Deutschland Gmbhaventis Pharma Deutschland Gmbh 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
HK1052183A1 (zh) 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6624155B2 (en) * 2001-05-01 2003-09-23 Board Of Trustees Of The University Of Arkansas Hybrid cholinergic agents and compositions
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
BR0213501A (pt) * 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
DE10259374A1 (de) * 2002-12-18 2004-07-08 Atto-Tec Gmbh Carboxamid-substituierte Farbstoffe für analytische Anwendungen
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7344701B2 (en) * 2004-02-03 2008-03-18 Biosearch Technologies, Inc. Xanthene dyes
WO2006073458A2 (en) 2004-04-30 2006-07-13 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
US8391785B2 (en) * 2005-04-29 2013-03-05 Impinj, Inc. Interference rejection in RFID tags
JP4913561B2 (ja) * 2006-11-17 2012-04-11 株式会社リコー コロナ帯電装置及び画像形成装置
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
RS57778B1 (sr) 2010-11-04 2018-12-31 Albireo Ab Inhibitori crevnog transportera žučne kiseline (ibat) za lečenje bolesti jetre
KR101890960B1 (ko) 2010-11-08 2018-09-28 알비레오 에이비 Ⅰｂａｔ 억제제 및 담즙산 바인더를 포함하는 약학적 조합물
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
MX2015013193A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal.
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JP2018199648A (ja) * 2017-05-29 2018-12-20 五稜化薬株式会社 新規トランスポーター機能解析用蛍光物質
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
EP3664782B1 (en) 2017-08-09 2025-01-29 Albireo AB Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
MX2020013774A (es) 2018-06-20 2021-03-02 Albireo Ab Modificaciones de cristales de odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
JP7504109B2 (ja) 2019-02-06 2024-06-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020167981A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US12037487B2 (en) 2020-10-09 2024-07-16 Polyplastics Co., Ltd. Polyacetal resin composition and automobile part
JP7078687B2 (ja) 2020-10-09 2022-05-31 ポリプラスチックス株式会社 ポリアセタール樹脂組成物及び自動車部品
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Ａｓｂｔ阻害剤の皮下投与
JP2025524362A (ja) 2022-06-09 2025-07-30 アルビレオ・アクチボラグ 肝炎の処置
CA3259103A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia (di)azepine compounds and their use as bile acid modulators
JP2025539895A (ja) 2022-12-09 2025-12-09 アルビレオ・アクチボラグ 腎臓の疾患の治療におけるａｓｂｔ阻害剤
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1119263B (de) 1959-07-09 1961-12-14 Riedel De Haeen Ag Verfahren zur Herstellung neuer Sulfonylurethane
US3859437A (en) 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US489423A (en) * 1893-01-03 Electric time-alarm
US417725A (en) * 1889-12-24 Coffin
US4217279A (en) * 1978-12-18 1980-08-12 Kaiser Emil T Synthesis of steroids
US4848349A (en) * 1987-04-29 1989-07-18 Sherman Igor A Substance and method for measuring hepatic blood flow
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
AU664059B2 (en) * 1991-12-20 1995-11-02 Hoechst Aktiengesellschaft Ethylenically unsaturated bile acid derivatives, processes for their preparation and precursors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1119263B (de) 1959-07-09 1961-12-14 Riedel De Haeen Ag Verfahren zur Herstellung neuer Sulfonylurethane
US3859437A (en) 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Ｃｈｅｍ．Ａｂｓ．，ｖｏｌ．１００，ａｂｓ．ｎｏ．３９６９ｓ
Ｃｈｅｍ．Ａｂｓ．，ｖｏｌ．１０３，ａｂｓ．ｎｏ．４３８６ｙ
Ｃｈｅｍ．Ａｂｓ．，ｖｏｌ．５５，ａｂｓ．ｎｏ．３６４８ｃ−ｅ
Ｃｈｅｍ．Ａｂｓ．，ｖｏｌ．９２，ａｂｓ．ｎｏ．７３３４５ａ
Ｊ．Ｍｅｄ．Ｃｈｅｍ．，（１９８４），２７，ｐ．７４６−９
Ｓｔｅｒｏｉｄｓ，（１９８３），４２（５），ｐ．５７５−９２
Ｓｔｅｒｏｉｄｓ，（１９９３），５３，ｐ．７９−８６
Ｔｅｔｒａｈｅｄｒｏｎ Ｌｅｔｔ．，（１９９２），３３（２），ｐ．１９５−８
Ｔｅｔｒａｈｅｄｒｏｎ Ｌｅｔｔ．，（１９９２），３３（３０），ｐ．４３２９−３２
Ｔｅｔｒａｈｅｄｒｏｎ Ｌｅｔｔ．，（１９９３），３４（５），ｐ．８１７−８
Ｔｅｔｒａｈｅｄｒｏｎ，（１９９２），４８（１０），ｐ．１８３７−５２

Also Published As

Publication number Publication date
KR100333151B1 (ko) 2002-09-04
EP0624594A2 (de) 1994-11-17
US5610151A (en) 1997-03-11
ES2136677T3 (es) 1999-12-01
CZ113794A3 (en) 1994-11-16
FI942077L (fi) 1994-11-09
NO304794B1 (no) 1999-02-15
HUT67574A (en) 1995-04-28
CA2123052A1 (en) 1994-11-09
EP0624594A3 (de) 1996-05-01
JPH072891A (ja) 1995-01-06
FI942077A0 (fi) 1994-05-05
CZ289209B6 (cs) 2001-12-12
DE59408602D1 (de) 1999-09-16
TW289021B (OSRAM) 1996-10-21
NO941680L (no) 1994-11-09
IL109580A (en) 1999-03-12
GR3031541T3 (en) 2000-01-31
NZ260471A (en) 1995-04-27
DK0624594T3 (da) 1999-12-13
AU673419B2 (en) 1996-11-07
HU9401408D0 (en) 1994-08-29
FI942077A7 (fi) 1994-11-09
EP0624594B1 (de) 1999-08-11
ATE183191T1 (de) 1999-08-15
NO941680D0 (no) 1994-05-06
IL109580A0 (en) 1994-08-26
CA2123052C (en) 2005-04-26
AU6194994A (en) 1994-11-10

Similar Documents

Publication Publication Date Title
JP3424978B2 (ja) 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤
JP3403218B2 (ja) 胆汁酸誘導体、その製造方法およびそれを含有する抗脂血剤
JPH07316186A (ja) ノル−胆汁酸誘導体、その製法および医薬としてのその使用
JP3476157B2 (ja) 胆汁酸のテトラゾール誘導体、その製法およびそれを含有する血中脂血低下剤
AU667009B2 (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
NO304187B1 (no) Fremstilling av dimere gallesyrederivater
JP3333210B2 (ja) 新規プレドニソロン誘導体および該化合物を含有する薬剤
WO1998027106A1 (en) Aminosterol ester compounds
US4265823A (en) Aurothiosteroids
EA001401B1 (ru) ЛАКТОНОВЫЕ ПРОИЗВОДНЫЕ 17β-КАРБОКСИ, КАРБОТИО И АМИД АНДРОСТАНОВ
JPH0559096A (ja) 新規アミノステロイド化合物
CN101300265A (zh) 糖皮质激素硝酰氧基衍生物
JP2636913B2 (ja) １７−ハロゲンメチレン−エストラトリエン、その製造方法および該化合物を含有する、エストロゲン欠乏症候群の治療用医薬
RU2257391C2 (ru) Производные фузидовой кислоты, стереоизомер, фармацевтические композиции, соединения
EP0470995A1 (en) USE OF STEROIDS AS AN ANTI-FUNGI AGENT.
US4390530A (en) 3-Deoxy-Δ15 -steroids
US3969503A (en) Compositions and methods useful in rendering lithogenic mammalian bile non-lithogenic
JP3096480B2 (ja) 胆汁酸不飽和誘導体、その製造方法、およびそれらを含有する製薬組成物

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090502

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100502

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110502

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110502

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120502

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130502

Year of fee payment: 10

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250